|
gptkbp:instanceOf
|
anabolic steroid
|
|
gptkbp:ATCCode
|
A14AB01
|
|
gptkbp:brand
|
gptkb:Deca-Durabolin
gptkb:Durabolin
|
|
gptkbp:CASNumber
|
434-22-0
|
|
gptkbp:chemicalFormula
|
C18H26O2
|
|
gptkbp:derivedFrom
|
testosterone
|
|
gptkbp:discoveredBy
|
1950
|
|
gptkbp:eliminationHalfLife
|
4.3 hours (free alcohol)
6-12 days (decanoate ester)
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:has_ester
|
gptkb:nandrolone_decanoate
gptkb:nandrolone_phenylpropionate
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
nandrolone
|
|
gptkbp:IUPACName
|
gptkb:(17β)-19-nortestosterone
|
|
gptkbp:legalStatus
|
controlled substance in many countries
|
|
gptkbp:MeSH_ID
|
D009292
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
274.40 g/mol
|
|
gptkbp:pregnancyCategory
|
X (contraindicated)
|
|
gptkbp:prohibits
|
gptkb:World_Anti-Doping_Agency
|
|
gptkbp:PubChem_CID
|
CHEMBL1433
9281
|
|
gptkbp:relatedTo
|
gptkb:boldenone
gptkb:trenbolone
testosterone
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:sideEffect
|
hair loss
acne
gynecomastia
suppression of natural testosterone
cardiovascular risk
|
|
gptkbp:UNII
|
6PG9VR430D
|
|
gptkbp:usedFor
|
treatment of osteoporosis
treatment of anemia
muscle wasting diseases
|
|
gptkbp:bfsParent
|
gptkb:anabolic_steroids
gptkb:Boldenone_undecylenate
gptkb:Montelaterone
|
|
gptkbp:bfsLayer
|
7
|